Leeward Investments LLC MA Has $12.68 Million Stake in Cencora, Inc. (NYSE:COR)

Leeward Investments LLC MA reduced its stake in Cencora, Inc. (NYSE:COR) by 20.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 56,348 shares of the company’s stock after selling 14,618 shares during the quarter. Leeward Investments LLC MA’s holdings in Cencora were worth $12,683,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. New Millennium Group LLC acquired a new stake in Cencora in the 2nd quarter valued at $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC bought a new stake in shares of Cencora during the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at approximately $30,000. Finally, Concord Wealth Partners acquired a new stake in shares of Cencora in the 3rd quarter valued at approximately $30,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Wells Fargo & Company upped their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Leerink Partners dropped their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Finally, Robert W. Baird cut their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Stock Performance

NYSE:COR opened at $245.38 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The stock has a 50 day simple moving average of $231.57 and a 200 day simple moving average of $230.64. Cencora, Inc. has a 1-year low of $191.11 and a 1-year high of $247.66. The stock has a market cap of $48.35 billion, a P/E ratio of 26.64, a PEG ratio of 1.49 and a beta of 0.44.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 6th. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.21 by $0.13. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $79.05 billion during the quarter, compared to analysts’ expectations of $77.68 billion. Research analysts anticipate that Cencora, Inc. will post 13.64 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is presently 22.15%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.